Compositions and methods of treating facioscapulohumeral muscular dystrophy
US-2024400707-A1 · Dec 5, 2024 · US
Method of boosting the immune response in neonates
US9499628B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9499628-B2 |
| Application number | US-201414304803-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 13, 2014 |
| Priority date | Jun 14, 2013 |
| Publication date | Nov 22, 2016 |
| Grant date | Nov 22, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In an aspect, a method of augmenting an immune response in a subject in need thereof, comprising identifying the subject, and treating the subject to inhibit the immune suppressive effect of CD71 + cells is provided. Further provided is a method of preventing, treating or ameliorating an infection in a subject, comprising administering to the subject an agent that reduces the level of CD71 + cells in the subject.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of augmenting an immune response in a subject in need thereof, comprising: a) identifying the subject; and b) administering to the subject an agent that specifically binds to CD71, wherein the agent that specifically binds to CD71 is an anti-CD71 antibody, wherein the subject is a neonate or a newborn, and wherein administration of the anti-CD71 antibody leads to an inhibition of an immune suppressive effect of CD71 + cells. 2. The method of claim 1 , wherein the anti-CD71 antibody is R17217. 3. The method of claim 1 , wherein the anti-CD71 antibody is C2F2. 4. A method of treating or ameliorating an infection in a subject, comprising administering to the subject an agent that reduces the level of CD71 + cells in the subject, wherein the agent specifically binds to CD71, wherein the agent is an anti-CD71 antibody, and wherein the subject is a neonate or a newborn. 5. The method of claim 4 , wherein the anti-CD71 antibody is a humanized antibody. 6. The method of claim 4 , wherein the anti-CD71 antibody is a human antibody. 7. The method of claim 4 , wherein the agent downregulates the level of CD71 + cells. 8. The method of claim 4 , comprising identifying the subject at risk for the infection. 9. The method of claim 1 , wherein the newborn is less than 28 days old. 10. The method of claim 4 , wherein the newborn is less than 28 or days old.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
- C07K16/2881Primary
against CD71 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9499628B2 cover?
- In an aspect, a method of augmenting an immune response in a subject in need thereof, comprising identifying the subject, and treating the subject to inhibit the immune suppressive effect of CD71 + cells is provided. Further provided is a method of preventing, treating or ameliorating an infection in a subject, comprising administering to the subject an agent that reduces the level of CD71 + …
- Who is the assignee on this patent?
- Children'S Hospital Medical Center
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2881. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).